CMG Pharmaceutical Co. Ltd - Asset Resilience Ratio
CMG Pharmaceutical Co. Ltd (058820) has an Asset Resilience Ratio of 6.66% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of CMG Pharmaceutical Co. Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how CMG Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. See CMG Pharmaceutical Co. Ltd (058820) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down CMG Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 058820 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩20.38 Billion | 6.66% |
| Total Liquid Assets | ₩20.38 Billion | 6.66% |
Asset Resilience Insights
- Limited Liquidity: CMG Pharmaceutical Co. Ltd maintains only 6.66% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CMG Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio
Compare CMG Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for CMG Pharmaceutical Co. Ltd (2011–2025)
The table below shows the annual Asset Resilience Ratio data for CMG Pharmaceutical Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.66% | ₩20.38 Billion ≈ $13.81 Million |
₩305.96 Billion ≈ $207.35 Million |
-17.79pp |
| 2024-12-31 | 24.46% | ₩74.21 Billion ≈ $50.29 Million |
₩303.44 Billion ≈ $205.63 Million |
-3.46pp |
| 2023-12-31 | 27.92% | ₩67.58 Billion ≈ $45.80 Million |
₩242.10 Billion ≈ $164.07 Million |
-6.48pp |
| 2022-12-31 | 34.40% | ₩73.36 Billion ≈ $49.71 Million |
₩213.26 Billion ≈ $144.52 Million |
-10.96pp |
| 2021-12-31 | 45.36% | ₩90.34 Billion ≈ $61.22 Million |
₩199.17 Billion ≈ $134.98 Million |
-10.84pp |
| 2020-12-31 | 56.19% | ₩109.78 Billion ≈ $74.39 Million |
₩195.36 Billion ≈ $132.39 Million |
-6.01pp |
| 2019-12-31 | 62.20% | ₩119.57 Billion ≈ $81.03 Million |
₩192.24 Billion ≈ $130.28 Million |
+14.58pp |
| 2018-12-31 | 47.62% | ₩54.46 Billion ≈ $36.91 Million |
₩114.38 Billion ≈ $77.51 Million |
-4.22pp |
| 2017-12-31 | 51.84% | ₩56.80 Billion ≈ $38.49 Million |
₩109.57 Billion ≈ $74.25 Million |
-1.47pp |
| 2016-12-31 | 53.31% | ₩59.16 Billion ≈ $40.09 Million |
₩110.98 Billion ≈ $75.21 Million |
+44.46pp |
| 2015-12-31 | 8.84% | ₩5.00 Billion ≈ $3.39 Million |
₩56.53 Billion ≈ $38.31 Million |
+8.37pp |
| 2014-12-31 | 0.48% | ₩278.19 Million ≈ $188.53K |
₩58.07 Billion ≈ $39.35 Million |
-0.02pp |
| 2013-12-31 | 0.50% | ₩278.19 Million ≈ $188.53K |
₩55.91 Billion ≈ $37.89 Million |
-52.64pp |
| 2012-12-31 | 53.14% | ₩30.35 Billion ≈ $20.57 Million |
₩57.11 Billion ≈ $38.70 Million |
+49.22pp |
| 2011-12-31 | 3.92% | ₩1.07 Billion ≈ $726.07K |
₩27.31 Billion ≈ $18.50 Million |
-- |
About CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more